Search

Your search keyword '"Byram, Kevin"' showing total 21 results
Start Over Author "Byram, Kevin" Search Limiters Available in Library Collection
21 results on '"Byram, Kevin"'

1. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

Author

Gorelik, Mark, primary, Chung, Sharon A., additional, Ardalan, Kaveh, additional, Binstadt, Bryce A., additional, Friedman, Kevin, additional, Hayward, Kristen, additional, Imundo, Lisa F., additional, Lapidus, Sivia K., additional, Kim, Susan, additional, Son, Mary Beth, additional, Sule, Sangeeta, additional, Tremoulet, Adriana H., additional, Van Mater, Heather, additional, Yildirim‐Toruner, Cagri, additional, Langford, Carol A., additional, Maz, Mehrdad, additional, Abril, Andy, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad, additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional

Published
2022
Full Text
View/download PDF

2. Kawasaki Disease: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments

Author

James, Karen E., primary, Kalot, Mohamad A., additional, Husainat, Nedaa M., additional, Dua, Anisha B., additional, Byram, Kevin, additional, Springer, Jason M., additional, Lin, Yih Chang, additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Gorelik, Mark, additional, Abril, Andy, additional, Langford, Carol, additional, Maz, Mehrdad, additional, Chung, Sharon A., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

3. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis

Author

Maz, Mehrdad, primary, Chung, Sharon A., additional, Abril, Andy, additional, Langford, Carol A., additional, Gorelik, Mark, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Imundo, Lisa F., additional, Kim, Susan, additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sule, Sangeeta, additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad A., additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

4. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis

Author

Chung, Sharon A., primary, Langford, Carol A., additional, Maz, Mehrdad, additional, Abril, Andy, additional, Gorelik, Mark, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Imundo, Lisa F., additional, Kim, Susan, additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sule, Sangeeta, additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad A., additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

5. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa

Author

Chung, Sharon A., primary, Gorelik, Mark, additional, Langford, Carol A., additional, Maz, Mehrdad, additional, Abril, Andy, additional, Guyatt, Gordon, additional, Archer, Amy M., additional, Conn, Doyt L., additional, Full, Kathy A., additional, Grayson, Peter C., additional, Ibarra, Maria F., additional, Imundo, Lisa F., additional, Kim, Susan, additional, Merkel, Peter A., additional, Rhee, Rennie L., additional, Seo, Philip, additional, Stone, John H., additional, Sule, Sangeeta, additional, Sundel, Robert P., additional, Vitobaldi, Omar I., additional, Warner, Ann, additional, Byram, Kevin, additional, Dua, Anisha B., additional, Husainat, Nedaa, additional, James, Karen E., additional, Kalot, Mohamad, additional, Lin, Yih Chang, additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Turner, Amy S., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

6. Giant Cell Arteritis: A Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments

Author

Dua, Anisha B., primary, Husainat, Nedaa M., additional, Kalot, Mohamad A., additional, Byram, Kevin, additional, Springer, Jason M., additional, James, Karen E., additional, Chang Lin, Yih, additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Abril, Andy, additional, Langford, Carol, additional, Maz, Mehrdad, additional, Chung, Sharon A., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

7. Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments

Author

Springer, Jason M., primary, Kalot, Mohamad A., additional, Husainat, Nedaa M., additional, Byram, Kevin W., additional, Dua, Anisha B., additional, James, Karen E., additional, Chang Lin, Yih, additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Abril, Andy, additional, Langford, Carol, additional, Maz, Mehrdad, additional, Chung, Sharon A., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

8. Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments

Author

Springer, Jason M., primary, Kalot, Mohamad A., additional, Husainat, Nedaa M., additional, Byram, Kevin W., additional, Dua, Anisha B., additional, James, Karen E., additional, Chang Lin, Yih, additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Abril, Andy, additional, Langford, Carol A., additional, Maz, Mehrdad, additional, Chung, Sharon A., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

9. Polyarteritis Nodosa: A Systematic Review of Test Accuracy and Benefits and Harms of Common Treatments

Author

Lin, Yih Chang, primary, Kalot, Mohamad A., additional, Husainat, Nedaa M., additional, Byram, Kevin, additional, Dua, Anisha B., additional, James, Karen E., additional, Springer, Jason M., additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Abril, Andy, additional, Langford, Carol, additional, Maz, Mehrdad, additional, Chung, Sharon A., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

10. Takayasu Arteritis: a Systematic Review and Meta‐Analysis of Test Accuracy and Benefits and Harms of Common Treatments

Author

Dua, Anisha B., primary, Kalot, Mohamad A., additional, Husainat, Nedaa M., additional, Byram, Kevin, additional, Springer, Jason M., additional, James, Karen E., additional, Chang Lin, Yih, additional, Turgunbaev, Marat, additional, Villa‐Forte, Alexandra, additional, Abril, Andy, additional, Langford, Carol, additional, Maz, Mehrdad, additional, Chung, Sharon A., additional, and Mustafa, Reem A., additional

Published
2021
Full Text
View/download PDF

11. Vasculitis as a Major Morbidity Factor in Patients With Partial RAG Deficiency

Author

Geier, Christoph B., primary, Farmer, Jocelyn R., additional, Foldvari, Zsofia, additional, Ujhazi, Boglarka, additional, Steininger, Jolanda, additional, Sleasman, John W., additional, Parikh, Suhag, additional, Dilley, Meredith A., additional, Pai, Sung-Yun, additional, Henderson, Lauren, additional, Hazen, Melissa, additional, Neven, Benedicte, additional, Moshous, Despina, additional, Sharapova, Svetlana O., additional, Mihailova, Snezhina, additional, Yankova, Petya, additional, Naumova, Elisaveta, additional, Özen, Seza, additional, Byram, Kevin, additional, Fernandez, James, additional, Wolf, Hermann M., additional, Eibl, Martha M., additional, Notarangelo, Luigi D., additional, Calabrese, Leonard H., additional, and Walter, Jolan E., additional

Published
2020
Full Text
View/download PDF

12. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

Author

Gorelik, Mark, Chung, Sharon A., Ardalan, Kaveh, Binstadt, Bryce A., Friedman, Kevin, Hayward, Kristen, Imundo, Lisa F., Lapidus, Sivia K., Kim, Susan, Son, Mary Beth, Sule, Sangeeta, Tremoulet, Adriana H., Van Mater, Heather, Yildirim‐Toruner, Cagri, Langford, Carol A., Maz, Mehrdad, Abril, Andy, Guyatt, Gordon, Archer, Amy M., Conn, Doyt L., Full, Kathy A., Grayson, Peter C., Ibarra, Maria F., Merkel, Peter A., Rhee, Rennie L., Seo, Philip, Stone, John H., Sundel, Robert P., Vitobaldi, Omar I., Warner, Ann, Byram, Kevin, Dua, Anisha B., Husainat, Nedaa, James, Karen E., Kalot, Mohamad, Lin, Yih Chang, Springer, Jason M., Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S., and Mustafa, Reem A.

Abstract

To provide evidence‐based recommendations and expert guidance for the management of Kawasaki disease (KD), focusing on clinical scenarios more commonly addressed by rheumatologists. Sixteen clinical questions regarding diagnostic testing, treatment, and management of KD were developed in the Patient/Population, Intervention, Comparison, and Outcomes (PICO) question format. Systematic literature reviews were conducted for each PICO question. We used the Grading of Recommendations, Assessment, Development and Evaluation method to assess the quality of evidence and formulate recommendations. Each recommendation required consensus from at least 70% of the Voting Panel. We present 1 good practice statement, 11 recommendations, and 1 ungraded position statement to guide the management of KD and clinical scenarios of suspected KD. These recommendations for KD are focused on situations in which input from rheumatologists may be requested by other managing specialists, such as in cases of treatment‐refractory, severe, or complicated KD. The good practice statement affirms that all patients with KD should receive initial treatment with intravenous immunoglobulin (IVIG). In addition, we developed 7 strong and 4 conditional recommendations for the management of KD or suspected KD. Strong recommendations include prompt treatment of incomplete KD, treatment with aspirin, and obtaining an echocardiogram in the setting of unexplained macrophage activation syndrome or shock. Conditional recommendations include use of IVIG with other adjuvant agents for patients with KD and high‐risk features of IVIG resistance and/or coronary artery aneurysms. These recommendations endorse minimizing risk to the patient by using established therapy promptly at disease onset and identifying situations in which adjunctive therapy may be warranted. These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and use of echocardiography in patients with suspected or confirmed KD.

Published
2022
Full Text
View/download PDF

15. 174. VASCULITIS AS A MAJOR MORBIDITY FACTOR IN PATIENTS WITH HYPOMORPHIC RAG VARIANTS

Author

Calabrese, Leonard, primary, Geier, Christoph, additional, Farmer, Jocelyn, additional, Foldvari, Zsofia, additional, Ujhazi, Boglarka, additional, Eibl, Martha, additional, Wolf, Hermann, additional, Sleasman, John, additional, Parikh, Suhag, additional, Dilley, Meredith, additional, Pai, Sung-Yun, additional, Henderson, Lauren, additional, Hazen, Melissa, additional, Neven, Benedicte, additional, Sharapova, Svetlana, additional, Mihailova, Snezhina, additional, Byram, Kevin, additional, Fernandez, James, additional, Yankova, Petya, additional, and Walter, Jolan, additional

Published
2019
Full Text
View/download PDF

16. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis

Author

Maz, Mehrdad, Chung, Sharon A., Abril, Andy, Langford, Carol A., Gorelik, Mark, Guyatt, Gordon, Archer, Amy M., Conn, Doyt L., Full, Kathy A., Grayson, Peter C., Ibarra, Maria F., Imundo, Lisa F., Kim, Susan, Merkel, Peter A., Rhee, Rennie L., Seo, Philip, Stone, John H., Sule, Sangeeta, Sundel, Robert P., Vitobaldi, Omar I., Warner, Ann, Byram, Kevin, Dua, Anisha B., Husainat, Nedaa, James, Karen E., Kalot, Mohamad A., Lin, Yih Chang, Springer, Jason M., Turgunbaev, Marat, Villa‐Forte, Alexandra, Turner, Amy S., and Mustafa, Reem A.

Abstract

To provide evidence‐based recommendations and expert guidance for the management of giant cell arteritis (GCA) and Takayasu arteritis (TAK) as exemplars of large vessel vasculitis. Clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for GCA and TAK (27 for GCA, 27 for TAK). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of the evidence. Recommendations were developed by the Voting Panel, comprising adult and pediatric rheumatologists and patients. Each recommendation required ≥70% consensus among the Voting Panel. We present 22 recommendations and 2 ungraded position statements for GCA, and 20 recommendations and 1 ungraded position statement for TAK. These recommendations and statements address clinical questions relating to the use of diagnostic testing, including imaging, treatments, and surgical interventions in GCA and TAK. Recommendations for GCA include support for the use of glucocorticoid‐sparing immunosuppressive agents and the use of imaging to identify large vessel involvement. Recommendations for TAK include the use of nonglucocorticoid immunosuppressive agents with glucocorticoids as initial therapy. There were only 2 strong recommendations; the remaining recommendations were conditional due to the low quality of evidence available for most PICO questions. These recommendations provide guidance regarding the evaluation and management of patients with GCA and TAK, including diagnostic strategies, use of pharmacologic agents, and surgical interventions.

Published
2021
Full Text
View/download PDF

19. 126. Development and validation of case-finding algorithms for the identification of patients with giant cell arteritis and takayasu's arteritis in large healthcare administrative databases.

Author

Annapureddy, Narender, Springer, Jason, Byram, Kevin, Casey, George, Cruz, Andy, Frangiosa, Vince, George, Michael, Maz, Mhrdad, Sharim, Rebecca, Sangani, Sapna, Liu, Mei, Merkel, Peter, and Sreih, Antoine

Subjects
CONFERENCES & conventions, ALGORITHMS, GIANT cell arteritis, NOSOLOGY, TAKAYASU arteritis
Published
2019
Full Text
View/download PDF

20. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa.

Author

Chung SA, Gorelik M, Langford CA, Maz M, Abril A, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot M, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, and Mustafa RA

Subjects
Cyclophosphamide therapeutic use, Disease Management, Glucocorticoids therapeutic use, Humans, United States, Antirheumatic Agents therapeutic use, Evidence-Based Medicine standards, Polyarteritis Nodosa diagnosis, Polyarteritis Nodosa diagnostic imaging, Polyarteritis Nodosa drug therapy, Rheumatology standards
Abstract

Objective: To provide evidence-based recommendations and expert guidance for the management of systemic polyarteritis nodosa (PAN)., Methods: Twenty-one clinical questions regarding diagnostic testing, treatment, and management were developed in the population, intervention, comparator, and outcome (PICO) format for systemic, non-hepatitis B-related PAN. Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel., Results: We present 16 recommendations and 1 ungraded position statement for PAN. Most recommendations were graded as conditional due to the paucity of evidence. These recommendations support early treatment of severe PAN with cyclophosphamide and glucocorticoids, limiting toxicity through minimizing long-term exposure to both treatments, and the use of imaging and tissue biopsy for disease diagnosis. These recommendations endorse minimizing risk to the patient by using established therapy at disease onset and identify new areas where adjunctive therapy may be warranted., Conclusion: These recommendations provide guidance regarding diagnostic strategies, use of pharmacologic agents, and imaging for patients with PAN., (© 2021 American College of Rheumatology. This article has been contributed to by US Government employees and their work is in the public domain in the USA.)

Published
2021
Full Text
View/download PDF

21. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Author

Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, and Mustafa RA

Subjects
Antibodies, Monoclonal, Humanized therapeutic use, Churg-Strauss Syndrome diagnosis, Churg-Strauss Syndrome drug therapy, Disease Management, Granulomatosis with Polyangiitis diagnosis, Granulomatosis with Polyangiitis drug therapy, Humans, Microscopic Polyangiitis diagnosis, Microscopic Polyangiitis drug therapy, Remission Induction, Rituximab therapeutic use, United States, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis diagnosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis drug therapy, Antirheumatic Agents therapeutic use, Evidence-Based Medicine standards, Rheumatology standards
Abstract

Objective: To provide evidence-based recommendations and expert guidance for the management of antineutrophil cytoplasmic antibody-associated vasculitis (AAV), including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA)., Methods: Clinical questions regarding the treatment and management of AAV were developed in the population, intervention, comparator, and outcome (PICO) format (47 for GPA/MPA, 34 for EGPA). Systematic literature reviews were conducted for each PICO question. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to assess the quality of evidence and formulate recommendations. Each recommendation required ≥70% consensus among the Voting Panel., Results: We present 26 recommendations and 5 ungraded position statements for GPA/MPA, and 15 recommendations and 5 ungraded position statements for EGPA. This guideline provides recommendations for remission induction and maintenance therapy as well as adjunctive treatment strategies in GPA, MPA, and EGPA. These recommendations include the use of rituximab for remission induction and maintenance in severe GPA and MPA and the use of mepolizumab in nonsevere EGPA. All recommendations are conditional due in part to the lack of multiple randomized controlled trials and/or low-quality evidence supporting the recommendations., Conclusion: This guideline presents the first recommendations endorsed by the American College of Rheumatology and the Vasculitis Foundation for the management of AAV and provides guidance to health care professionals on how to treat these diseases., (© 2021, American College of Rheumatology.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results